First-Line Bavencio Bladder Cancer OK Boosts Merck KGaA
EU Approval Will Bolster Sales
Pfizer-partnered Bavencio has struggled to compete with other checkpoint inhibitors like Keytruda, Opdivo, Imfinzi and Tecentriq, but could carve out a lucrative niche in first-line urothelial carcinoma.
